Ultragenyx Wins FDA Approval For FAYUVI In Pediatric MPS IIIA

Ultragenyx Pharmaceutical received FDA standard full approval for FAYUVI (UX111) to treat pediatric patients with mucopolysaccharidosis type IIIA, or Sanfilippo syndrome Type A. The approval creates a commercial opportunity in a rare pediatric disease with significant unmet medical need and is a major positive catalyst for Ultragenyx.